170 related articles for article (PubMed ID: 29425253)
1. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
[TBL] [Abstract][Full Text] [Related]
2. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.
Huang C; Shen S; Ma Q; Chen J; Gill A; Pollock CA; Chen XM
Diabetes; 2013 Aug; 62(8):2923-34. PubMed ID: 23656889
[TBL] [Abstract][Full Text] [Related]
3. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.
Huang C; Shen S; Ma Q; Gill A; Pollock CA; Chen XM
Nephrol Dial Transplant; 2014 Feb; 29(2):313-24. PubMed ID: 24166472
[TBL] [Abstract][Full Text] [Related]
4. High glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channel.
Huang C; Pollock CA; Chen XM
PLoS One; 2014; 9(4):e95173. PubMed ID: 24733189
[TBL] [Abstract][Full Text] [Related]
5. KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
Huang C; Lin MZ; Cheng D; Braet F; Pollock CA; Chen XM
Sci Rep; 2016 Mar; 6():23884. PubMed ID: 27029904
[TBL] [Abstract][Full Text] [Related]
6. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
Zhang H; Saha J; Byun J; Schin M; Lorenz M; Kennedy RT; Kretzler M; Feldman EL; Pennathur S; Brosius FC
Am J Physiol Renal Physiol; 2008 Oct; 295(4):F1071-81. PubMed ID: 18667486
[TBL] [Abstract][Full Text] [Related]
8. Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy reduces extracellular matrix production without regression of fibrosis.
Conway BR; Betz B; Sheldrake TA; Manning JR; Dunbar DR; Dobyns A; Hughes J; Mullins JJ
Nephrology (Carlton); 2014 Dec; 19(12):802-13. PubMed ID: 25196678
[TBL] [Abstract][Full Text] [Related]
9. Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.
Wilson PG; Thompson JC; Yoder MH; Charnigo R; Tannock LR
J Lipid Res; 2017 Dec; 58(12):2264-2274. PubMed ID: 28912302
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of allicin on streptozotocin-induced diabetic nephropathy in rats.
Huang H; Jiang Y; Mao G; Yuan F; Zheng H; Ruan Y; Wu T
J Sci Food Agric; 2017 Mar; 97(4):1359-1366. PubMed ID: 27363537
[TBL] [Abstract][Full Text] [Related]
11. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.
You H; Gao T; Cooper TK; Morris SM; Awad AS
Kidney Int; 2013 Dec; 84(6):1189-97. PubMed ID: 23760286
[TBL] [Abstract][Full Text] [Related]
12. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.
Gu C; Zhang J; Noble NA; Peng XR; Huang Y
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457
[TBL] [Abstract][Full Text] [Related]
13. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
14. Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.
Barutta F; Bellini S; Mastrocola R; Gambino R; Piscitelli F; di Marzo V; Corbetta B; Vemuri VK; Makriyannis A; Annaratone L; Bruno G; Gruden G
Br J Pharmacol; 2018 Dec; 175(23):4371-4385. PubMed ID: 30184259
[TBL] [Abstract][Full Text] [Related]
15. Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.
Li X; Cai W; Lee K; Liu B; Deng Y; Chen Y; Zhang X; He JC; Zhong Y
Sci Rep; 2017 Nov; 7(1):14603. PubMed ID: 29097815
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway.
Wang D; Zhang G; Chen X; Wei T; Liu C; Chen C; Gong Y; Wei Q
Int J Mol Med; 2018 May; 41(5):2784-2792. PubMed ID: 29484381
[TBL] [Abstract][Full Text] [Related]
18. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy.
Yung S; Chau MK; Zhang Q; Zhang CZ; Chan TM
PLoS One; 2013; 8(1):e54501. PubMed ID: 23349910
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of KCa3.1 suppresses TGF-β1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways.
Huang C; Day ML; Poronnik P; Pollock CA; Chen XM
Int J Biochem Cell Biol; 2014 Feb; 47():1-10. PubMed ID: 24291552
[TBL] [Abstract][Full Text] [Related]
20. Protective role of low-dose TGF-β1 in early diabetic nephropathy induced by streptozotocin.
Ma X; Ding J; Min H; Wen Y; Gao Q
Int Immunopharmacol; 2013 Nov; 17(3):752-8. PubMed ID: 24055008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
